Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 May 13;137(19):2570-2571.
doi: 10.1182/blood.2020009850.

Outcomes for PTCL: which pathway to success?

Julie M Vose  1
Affiliations
Editorial

Outcomes for PTCL: which pathway to success?

Julie M Vose. Blood. .
No abstract available

PubMed Disclaimer

Figures

None
The predominant cause of failure with auto-SCT is relapse compared to nonrelapse mortality with allo-SCT for PTCL. See Figure 3A-B in the article by Schmitz et al that begins on page 2646.
See this image and copyright information in PMC

Comment on

  • A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
    Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, Jaccard A, Reimer P, Wagner E, Wilhelm M, Sanhes L, Lamy T, de Leval L, Rosenwald A, Roussel M, Kroschinsky F, Lindemann W, Dreger P, Viardot A, Milpied N, Gisselbrecht C, Wulf G, Gyan E, Gaulard P, Bay JO, Glass B, Poeschel V, Damaj G, Sibon D, Delmer A, Bilger K, Banos A, Haenel M, Dreyling M, Metzner B, Keller U, Braulke F, Friedrichs B, Nickelsen M, Altmann B, Tournilhac O. Schmitz N, et al. Blood. 2021 May 13;137(19):2646-2656. doi: 10.1182/blood.2020008825. Blood. 2021. PMID: 33512419 Free PMC article. Clinical Trial.

References

    1. Schmitz N, Truemper L, Bouabdallah K, et al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood. 2021;137(19):2646-2656. - PMC - PubMed
    1. Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418-3425. - PubMed
    1. Horwitz S, O’Connor OA, Pro B, et al; ECHELON-2 Study Group . Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial [published correction appears in Lancet. 2019;393(10168):228]. Lancet. 2019;393(10168):229-240. - PMC - PubMed
    1. Savage KJ, Horwitz SM, Advani RH, et al. An exploratory analysis of brentuximab vedotin plus CHP (A + CHP) in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas (ECHELON-2): impact of consolidative stem cell transplant [abstract]. Blood. 2019;134(suppl 1). Abstract 624.
    1. Lunning MH, Mehta-Shah M, Moskowitz A, et al. Phase I/II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T cell non-Hodgkin lymphoma: Phase I results from the T-cell consortium. Hematol Oncol. 2017;35:411-412.

MeSH terms